Protocol Ledger

NCT06865417 · Phase III · RECRUITING

A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis

Interventional Phase III clinical trial protocol NCT06865417 sponsored by Alfasigma S.p.A in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-09-29 Enrollment: 80 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06865417
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)80 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06865417
Protocol FieldVerified Registry Value
NCT IdentifierNCT06865417
Consolidated Lead SponsorAlfasigma S.p.A
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment80 participants (ESTIMATED)
Registered Start Date2025-09-29
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI